Auro Laboratories Ltd vs Emcure Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Auro Laboratories Ltd is ₹ 240 as of 04 May 10:45 . The P/E Ratio of Auro Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Emcure Pharmaceuticals Ltd changed from 29.8 on March 2025 to 29.8 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Auro Laboratories Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 20327 crore on March 2025 to ₹ 20327 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Auro Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Emcure Pharmaceuticals Ltd for the Dec '25 is ₹ 2365 crore as compare to the Mar '25 revenue of ₹ 2120 crore. This represent the growth of 11.54% The ebitda of Auro Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Emcure Pharmaceuticals Ltd for the Dec '25 is ₹ 456.45 crore as compare to the Mar '25 ebitda of ₹ 396.48 crore. This represent the growth of 15.13% The net profit of Auro Laboratories Ltd changed from ₹ 0.75 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 152.59 crore to ₹ 231.37 crore over 7 quarters. This represents a CAGR of 26.85% The Dividend Payout of Auro Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Emcure Pharmaceuticals Ltd changed from 4.3 % on March 2021 to 17.92 % on March 2025 . This represents a CAGR of 33.04% over 5 years .

About Auro Laboratories Ltd

Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API).
Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes.
The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra.
The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments.

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

FAQs for the comparison of Auro Laboratories Ltd and Emcure Pharmaceuticals Ltd

Which company has a larger market capitalization, Auro Laboratories Ltd or Emcure Pharmaceuticals Ltd?

Market cap of Auro Laboratories Ltd is 149 Cr while Market cap of Emcure Pharmaceuticals Ltd is 31,850 Cr

What are the key factors driving the stock performance of Auro Laboratories Ltd and Emcure Pharmaceuticals Ltd?

The stock performance of Auro Laboratories Ltd and Emcure Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Auro Laboratories Ltd and Emcure Pharmaceuticals Ltd?

As of May 4, 2026, the Auro Laboratories Ltd stock price is INR ₹239.1. On the other hand, Emcure Pharmaceuticals Ltd stock price is INR ₹1679.95.

How do dividend payouts of Auro Laboratories Ltd and Emcure Pharmaceuticals Ltd compare?

To compare the dividend payouts of Auro Laboratories Ltd and Emcure Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.